Recently added

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Coveler, Andrew; Reilley, Matthew; Zalupski, Mark; Ponz-Sarvise, Mariano; Fountzilas, Christos; Macarulla, Teresa (American Association for Cancer Research, 2024-10-15)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Jiménez, Miguel Martín; Shimizu, Toshio; Keam, Bhumsuk; Rutten, Annemie; Curigliano, Giuseppe; Meric-Bernstam, Funda; GARRALDA, Elena (Elsevier, 2024-08)

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Martinez-Quintanilla, Jordi; Cabot Romero, Débora; Sabia, Domenico; Vergés, Jordi; CHICOTE, IRENE; Cabellos, Laia; Alcántara , Anna Maria; Jiménez Catalán, Juan José; Muñoz-Torres, Pau Marc; Nonell, Lara; Flores, Raquel; Arqués, Oriol; Ros, Javier; Elez, Elena; Tabernero, Josep; Palmer, Hector (American Association for Cancer Research, 2024-09-15)

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Bordenave, Stephanie; Reck, Martin; Ciuleanu, Tudor Eliade; Schenker, Michael; cobo, manuel; Juan-Vidal, Oscar; FELIP, ENRIQUETA (Elsevier, 2024-11)

Editorial: MYC as a disease target beyond cancer

Whitfield, Jonathan (Frontiers Media, 2024-08-22)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Editorial: MYC as a disease target beyond cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma ﻿

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies ﻿

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei ﻿

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial ﻿

Editorial: MYC as a disease target beyond cancer ﻿

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Editorial: MYC as a disease target beyond cancer